Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAB: Functional Analysis of BRCAness
NL-OMON50644Phase 2Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olaparib in ovarian cancer and epithelial ovarian cancer (EOC), sponsored by Amsterdam University Medical Center. Primary endpoint: Objective response rate correlation by RAD51 assay. Started Jan 2019; status: completed.
02
Drugs
olaparib
03
Conditions
ovarian cancerepithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on NL-OMON50644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50644.